The presence of iron within atheromatous plaques is thought to contribute to the pathogenesis of atherosclerosis. The "hemochromatosis paradox," as referred to in the recent article by Sullivan, 1 originates from the observation that despite significant iron overload, patients with hereditary hemochromatosis (HH) are not at increased risk for atherosclerosis. A number of reasons for this have been proposed, not least is the finding of favorable lipid profiles in C282Y homozygotes compared with wild-type controls. 2 The majority of patients with HH are homozygous for the C282Y mutation of the HFE gene. HFE-HH is characterized by the inability of iron to induce hepcidin, the chief iron regulatory hormone. Failure of hepcidin to degrade ferroportin, an iron export molecule, results in excessive iron release from duodenal enterocytes and macrophages, causing systemic iron overload. 3 Reduced intramacrophage iron levels may lead to defective macrophage function and even diminished foam cell formation, potentially providing protection from atherogenesis. 1 Although an attractive hypothesis, the mechanism underlying this finding remains unclear.
